Cannabis oil fails to ease Parkinson’s pain in trial

There is a lack of treatments for non-motor symptoms (NMS) in Parkinson's disease (PD). To assess the safety and effectiveness of an oral Cannabis sativa L. extract on pain and other NMS of PD. This phase II, randomized, placebo-controlled trial evaluated a formulation containing cannabidiol (CBD; 96 mg/ml) and Δ9-tetrahydrocannabinol (THC; 2.1 mg/ml) in PD patients with chronic pain over 9 weeks. The final daily dosage was 43.88 mg CBD and 0.96 mg THC. The primary outcome was the between-group difference in PD-Pain Classification System (PCS) scores at final visit. We enrolled 101 participants, and 87 completed the study. No significant differences were observed between the CBD/THC and placebo groups in PD-PCS scores (P = 0.757) or in other non-motor scales. No serious adverse events were reported. A cannabis oil formulation did not improve pain or other NMS compared with placebo in people with PD. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.